1998Phase 1–2 human evidence
Evidence strength B · 70/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 60/100
- Directness
- 88/100
- Population relevance
- 65/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.
Following i.v. bolus injection, plasma concentrations of the peptides declined biexponentially. Ipamorelin differed markedly from the other peptides investigated, demonstrating a systemic plasma clearance 5-fold lower than that of GHRP-6. Ipamorelin was mainly excre …
- Authors
- Johansen PB, Hansen KT, Andersen JV, Johansen NL.
- Source
- peer_reviewed_research
- DOI
- 10.1080/004982598238976
- PubMed
- 9879640
Open original source2014Phase 1–2 human evidence
Evidence strength B · 74/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 68/100
- Directness
- 88/100
- Population relevance
- 78/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.
Overall incidence of any treatment-emergent adverse events was 87.5 % in the ipamorelin group and 94.8 % in placebo group. Median time to first tolerated meal was 25.3 and 32.6 h in the ipamorelin and placebo groups, respectively (p = 0.15). LIMITATIONS: This proof …
1999Phase 1–2 human evidence
Evidence strength B · 70/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 60/100
- Directness
- 88/100
- Population relevance
- 65/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.
The ipamorelin-GH concentration relationship was characterized using an indirect response model and population fitting. ...CONCLUSIONS: The proposed PK/PD model provides a useful characterization of ipamorelin disposition and GH responses across a range of doses....
2026Phase 1–2 human evidence
Evidence strength B · 76/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 68/100
- Directness
- 88/100
- Population relevance
- 78/100
- Reporting quality
- 68/100
- Replication
- 72/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
Search terms included "peptide therapeutics," "aging," "gerontology," "healthspan," combined with specific peptide names (tirzepatide, epitalon, GHK-Cu, BPC-157, TB-500, Semax, CJC-1295, ipamorelin, bremelanotide). Peer-reviewed articles, clinical trials, regulatory docume …
2026Phase 1–2 human evidence
Evidence strength C · 63/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 68/100
- Directness
- 45/100
- Population relevance
- 78/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (anti-obesity drug 9604), BPC-157 (body protection compound 157), CJC-1295, FS-344 (fol …
2009Animal research
Evidence strength C · 60/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 46/100
- Directness
- 88/100
- Population relevance
- 25/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats.
OBJECTIVES: Growth hormone (GH) reduces the catabolic side effects of steroid treatment via effects on the amino-nitrogen metabolism. Ipamorelin is a synthetic peptide with GH releasing properties. We wished to study the metabolic effects of Ipamorelin and GH on sel …
2001Animal research
Evidence strength C · 60/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 46/100
- Directness
- 88/100
- Population relevance
- 25/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.
In +/lit and lit/lit mice ipamorelin induced a small (15%) increase in body weight by 2 weeks, that was not further augmented by 9 weeks. GH treatment markedly enhanced body weight in both groups. Ipamorelin also increased fat pad weights relative to body weight in …
2002Animal research
Evidence strength C · 60/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 46/100
- Directness
- 88/100
- Population relevance
- 25/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.
In the Ipamorelin group alone, in vitro treatment with Ipamorelin (10(-8) M), or GHRP 6 (10(-8) M), or GHRH (10(-8) M) for 4 hours, increased the percentage of somatotroph cells, without modifying the ratio of strongly/weakly immunostained GH cells. Basal intracellu …
1999Animal research
Evidence strength C · 60/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 46/100
- Directness
- 88/100
- Population relevance
- 25/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.
The responsiveness of the pituitary to a provocative i.v. dose of ipamorelin or GHRH showed that the plasma GH response was marginally reduced (P<0.03) after ipamorelin, but unchanged after GHRH. The pituitary GH content was unchanged by ipamorelin treatme …
2001Animal research
Evidence strength C · 60/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 46/100
- Directness
- 88/100
- Population relevance
- 25/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.
The ability of the growth hormone secretagogue (GHS) Ipamorelin to counteract the catabolic effects of glucocorticoid (GC) on skeletal muscles and bone was investigated in vivo in an adult rat model. Groups of 8-month-old female rats were injected subcutaneously for 3 mont …
2026Laboratory research
Evidence strength C · 63/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 42/100
- Directness
- 88/100
- Population relevance
- 30/100
- Reporting quality
- 68/100
- Replication
- 72/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
PURPOSE: To summarize existing peer-reviewed data on 6 emerging peptides (BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu [copper peptide]) for musculoskeletal recovery and enhancement in animal and human models. ...METHODS: Three independent r …
1998Laboratory research
Evidence strength C · 58/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 42/100
- Directness
- 88/100
- Population relevance
- 18/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Ipamorelin, the first selective growth hormone secretagogue.
The development and pharmacology of a new potent growth hormone (GH) secretagogue, ipamorelin, is described. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), which displays high GH releasing potency and efficacy in vitro and in vivo. ...The specificity …
2026Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 42/100
- Directness
- 88/100
- Population relevance
- 30/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
Key peptides evaluated included BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu. RESULTS: BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. ...TB-4 and its derivative TB-50 …
2026Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 42/100
- Directness
- 88/100
- Population relevance
- 30/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation, whereas growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 activate IGF …
2026Laboratory research
Evidence strength C · 63/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 42/100
- Directness
- 88/100
- Population relevance
- 30/100
- Reporting quality
- 68/100
- Replication
- 72/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.
Marketed as more selective and ostensibly safer alternatives, peptides-including growth hormone secretagogues (e.g., Ipamorelin), growth hormone-releasing hormone analogues (e.g., CJC-1295, Sermorelin), and synthetic fragments (e.g., Frag 176-191, KPV)-are promoted for mus …
2020Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 42/100
- Directness
- 88/100
- Population relevance
- 30/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics.
Here, we investigate the efficacy of peripherally restricted (ipamorelin) and a globally active (HM01) selective ghrelin receptor agonist in an experimental model of non-inflammatory visceral hypersensitivity and somatic mechanical allodynia. ...RESULTS: Compared to vehicl …
2009Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 42/100
- Directness
- 88/100
- Population relevance
- 30/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.
In contrast, repetitive dosing of ipamorelin (0.1 or 1 mg/kg) significantly increased the cumulative fecal pellet output, food intake, and body weight gain. The results suggest that postsurgical intravenous infusions of ipamorelin may ameliorate the symptoms in pati …
2024Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 42/100
- Directness
- 88/100
- Population relevance
- 30/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.
The objective of this study was to examine the impact of ipamorelin acetate (IPA), a ghrelin agonist, on the reproductive axis of the tilapia Oreochromis mossambicus. ...
2026Laboratory research
Evidence strength C · 63/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 42/100
- Directness
- 88/100
- Population relevance
- 30/100
- Reporting quality
- 68/100
- Replication
- 72/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
Regenerative peptides (e.g., body protection compound-157 and thymosin derivatives) and growth hormone axis secretagogues (e.g., CJC-1295, ipamorelin, and tesamorelin) remain investigational, with uncertain safety profiles, product quality concerns, and widespread antidopi …
2026Laboratory research
Evidence strength D · 49/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 42/100
- Directness
- 45/100
- Population relevance
- 30/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
The agents most commonly encountered in clinical practice and online self-administration protocols include growth hormone-releasing hormone (GHRH) analogues (e.g., sermorelin, tesamorelin, CJC-1295 with Drug Affinity Complex [DAC], CJC-1295 without DAC), growth hormone secretagog …
2012Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 42/100
- Directness
- 88/100
- Population relevance
- 30/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.
The goal of this study was to investigate whether ipamorelin, a synthetic peptidomimetic that acts on the ghrelin receptor, accelerates gastric emptying in a rodent model of gastroparesis induced by abdominal surgery and intestinal manipulation. ...Following abdominal surg …
2018Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 42/100
- Directness
- 88/100
- Population relevance
- 30/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Analysis of new growth promoting black market products.
Additionally, three analogues of GHRPs were identified as Gly-GHRP-6, Gly-GHRP-2 and Gly-Ipamorelin, representing the corresponding GHRP extended by a N-terminal glycine residue. The structure of these peptides was characterised by means of high resolution (tandem) mass sp …
2024Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 42/100
- Directness
- 88/100
- Population relevance
- 30/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.
This study investigated whether ghrelin mimetics, namely anamorelin and ipamorelin, can alleviate weight loss and inhibition of feeding observed during acute and delayed phases of cisplatin-induced emesis in ferrets. The potential of anamorelin to inhibit electrical field …
2020Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 42/100
- Directness
- 88/100
- Population relevance
- 30/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.
The GHS that will be discussed include sermorelin, growth hormone-releasing peptides (GHRP)-2, GHRP-6, ibutamoren, and ipamorelin. All are potent GH and IGF-1 stimulators that can significantly improve body composition while ameliorating specific hypogonadal symptoms inclu …
2026Laboratory research
Evidence strength D · 49/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Source authority
- 78/100
- Study design and bias control
- 42/100
- Directness
- 45/100
- Population relevance
- 30/100
- Reporting quality
- 68/100
- Replication
- 45/100
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
This peer-reviewed source examines Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.